プリオン病治療市場-世界の産業規模、シェア、動向、機会、予測、タイプ別（ヒトプリオン病、動物プリオン病）、薬剤別（抗うつ薬、抗精神病薬）、地域別、競合別、2020年～2030年

世界のプリオン病治療市場は、2024年に49億7,000万米ドルと評価され、予測期間中にCAGR4.49％で成長し、2030年までには64億7,000万米ドルに達すると予測されています。

プリオン病、すなわち伝達性海綿状脳症（TSEs）は、脳内にミスフォールディングしたプリオンタンパク質が異常に蓄積することで生じる、まれで致死的な神経変性疾患です。これには、クロイツフェルトヤコブ病（CJD）、変異型CJD（vCJD）、致死性家族性不眠症（FFI）などの疾患が含まれます。市場開拓は、疾患に対する認識の高まり、診断法の改善、効果的な治療法の開発を目指した研究開発の活発化などに支えられ、着実に拡大しています。治療法は存在しないものの、現在の治療アプローチは症状の管理と患者のQOLに重点を置いた支持的なものです。ヒトプリオン病は、より高い有病率と研究活動により、主要なセグメントとなっています。抗うつ薬は、神経症状や精神症状を管理する役割を担っているため、主要な薬剤クラスとなっています。診断の複雑さ、低い罹患率、限られた治療選択肢などの課題があるにもかかわらず、バイオマーカー調査、神経変性研究への資金提供、先進的な治療法の探求における革新が、市場の成長をさらに促進すると予想されます。

市場促進要因

プリオン病の有病率の増加

主な市場課題

プリオン病に対する限られた理解

主要市場動向

新たな治療アプローチ

• プリオン複製を破壊し、神経毒性を軽減する低分子開発が行われています。
• モノクローナル抗体は、ミスフォールディングしたプリオンタンパク質に結合し、中和する可能性が検討されています。
• アンチセンス・オリゴヌクレオチド（ASO）やRNA干渉（RNAi）などRNAベース治療法は、プリオンタンパク質異常産生を抑制したり、そ分解を促進したりすることを目的としています。
• CRISPR-Cas9を含む遺伝子治療技術は、遺伝性プリオン障害原因となる遺伝子変異修正に有望です。

これらの革新的な治療法は、その大部分が実験段階であるが、将来の疾患修飾治療に希望を与えるものであり、投資と研究の関心が高まっています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のプリオン病治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（ヒトプリオン病、動物プリオン病）
  • 薬剤別（抗うつ薬、抗精神病薬）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米のプリオン病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のプリオン病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋のプリオン病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のプリオン病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのプリオン病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のプリオン病治療市場：SWOT分析

第14章 競合情勢

• Fresenius SE & Co. KGaA
• Elite Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• Novartis AG
• Merck KGaA
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Cipla Ltd
• Teva Pharmaceuticals
• Abbott Laboratories

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Prion Disease Treatment Market was valued at USD 4.97 Billion in 2024 and is projected to reach USD 6.47 Billion by 2030, growing at a CAGR of 4.49% during the forecast period. Prion diseases, or transmissible spongiform encephalopathies (TSEs), are rare, fatal neurodegenerative disorders resulting from the abnormal accumulation of misfolded prion proteins in the brain. These include conditions such as Creutzfeldt-Jakob Disease (CJD), variant CJD (vCJD), Fatal Familial Insomnia (FFI), and others. The market is witnessing steady expansion, supported by greater disease awareness, improved diagnostics, and increased research initiatives aimed at developing effective therapies. While no cure exists, current treatment approaches are largely supportive, focusing on symptom management and patient quality of life. Human prion diseases are the dominant segment, driven by higher prevalence and research activity. Antidepressants represent the leading drug class due to their role in managing neurological and psychiatric symptoms. Innovations in biomarker research, funding for neurodegenerative studies, and exploration of advanced therapeutic methods are expected to further propel market growth, despite challenges such as diagnostic complexity, low incidence rates, and limited treatment options.

Key Market Drivers

Increasing Prevalence of Prion Diseases

The rising incidence of prion diseases globally is a major growth driver for the treatment market. These neurodegenerative disorders, though rare, are increasingly diagnosed due to advancements in medical technology and growing awareness among healthcare professionals. Enhanced diagnostic capabilities have made it possible to identify cases that were previously misdiagnosed or undetected, contributing to a perceived rise in prevalence. Additionally, the aging global population has amplified the incidence of diseases like sporadic CJD, which is more common in older adults. According to the National Library of Medicine, at least 485 cases of iatrogenic CJD (iCJD) have been documented worldwide, most of which occurred prior to 2012. These included cases linked to contaminated surgical tools, EEG needles, corneal transplants, and notably, human-derived growth hormones and dura mater grafts. As detection improves and awareness increases, the demand for prion disease treatments is expected to grow steadily.

Key Market Challenges

Limited Understanding of Prion Diseases

A major challenge hindering the development of effective prion disease therapies is the limited understanding of the diseases' underlying mechanisms. Prion disorders are complex, and their pathogenesis-particularly how prions replicate and cause neurodegeneration-remains only partially understood. This knowledge gap restricts the identification of viable drug targets and slows down therapeutic innovation. The intricacy of prion biology requires extensive research to unravel molecular pathways before advancing drug discovery. This lack of foundational understanding poses a significant barrier to the timely development and approval of effective treatments.

Key Market Trends

Emerging Therapeutic Approaches

Innovative treatment strategies are emerging as key trends in the prion disease treatment landscape. Researchers are investigating a range of novel approaches to halt or reverse disease progression.

• Small molecules are being developed to disrupt prion replication and reduce neurotoxicity.
• Monoclonal antibodies are being explored for their potential to bind and neutralize misfolded prion proteins.
• RNA-based therapies, such as antisense oligonucleotides (ASOs) and RNA interference (RNAi), aim to suppress abnormal prion protein production or promote its breakdown.
• Gene therapy techniques, including CRISPR-Cas9, show promise for correcting genetic mutations responsible for inherited prion disorders.

These therapeutic innovations, though largely in experimental phases, offer hope for disease-modifying treatments in the future and are attracting increasing investment and research attention.

Key Market Players

• Fresenius SE & Co. KGaA
• Elite Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• Novartis AG
• Merck KGaA
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Cipla Ltd
• Teva Pharmaceuticals
• Abbott Laboratories

Report Scope:

In this report, the Global Prion Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prion Disease Treatment Market, By Type:

• Human Prion Diseases
• Animal Prion Diseases

Prion Disease Treatment Market, By Drug:

• Antidepressant
• Antipsychotic Agents

Prion Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prion Disease Treatment Market.

Available Customizations:

Global Prion Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prion Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Human Prion Diseases, Animal Prion Diseases)
  • 5.2.2. By Drug (Antidepressant, Antipsychotic Agents)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Prion Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prion Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug
  • 6.3.2. Canada Prion Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug
  • 6.3.3. Mexico Prion Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug

7. Europe Prion Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prion Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug
  • 7.3.2. United Kingdom Prion Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug
  • 7.3.3. Italy Prion Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug
  • 7.3.4. France Prion Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug
  • 7.3.5. Spain Prion Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug

8. Asia-Pacific Prion Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Prion Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug
  • 8.3.2. India Prion Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug
  • 8.3.3. Japan Prion Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug
  • 8.3.4. South Korea Prion Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug
  • 8.3.5. Australia Prion Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug

9. South America Prion Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Prion Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug
  • 9.3.2. Argentina Prion Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug
  • 9.3.3. Colombia Prion Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug

10. Middle East and Africa Prion Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Prion Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug
  • 10.3.2. Saudi Arabia Prion Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug
  • 10.3.3. UAE Prion Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Prion Disease Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Fresenius SE & Co. KGaA
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Elite Pharmaceuticals Inc
• 14.3. Ionis Pharmaceuticals Inc
• 14.4. Novartis AG
• 14.5. Merck KGaA
• 14.6. AstraZeneca PLC
• 14.7. Bristol-Myers Squibb Company
• 14.8. Cipla Ltd
• 14.9. Teva Pharmaceuticals
• 14.10. Abbott Laboratories

15. Strategic Recommendations

16. About Us & Disclaimer